Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 28.7% from a year ago
Other current liabilities stood at $6.48M at the end of Q1 FY2026, up 28.7% from a year earlier and down 7.7% from the prior quarter. Over 3 fiscal years it compounded at +42.6% a year.
Context
- Other current liabilities amounted to 25.5% of total assets at the end of Q1 FY2026, up 8.8 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +28.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.91M USD
- Year-over-year change
- +24.3%
- 4-year CAGR
- +164.1%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.91M | +24.3% |
| FY2024 | 2024-12-31 | 5.56M | +46.3% |
| FY2023 | 2023-12-31 | 3.8M | +59.5% |
| FY2022 | 2022-12-31 | 2.38M | +1576.8% |
| FY2021 | 2021-12-31 | 142K | — |
Other Current Liabilities vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 other current liabilities of $6.48M is the 6th highest of the 11 companies compared; the peer median is $5.86M.
- Its year-over-year change of +28.7% is the 5th highest of 10, against a peer median of +21.4%.
- Other current liabilities amounts to 25.5% of total assets for NVCT, versus a peer median of 1.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.11B | +304928.8% | +7.5% | 1.4% | |
| Mar 2026 | $18.45M | — | -8.5% | 8.5% | |
| Mar 2026 | $18.2M | -30.4% | +150.6% | 3.9% | |
| Jun 2026 | $13M | +360.5% | +153.8% | 1.7% | |
| Mar 2026 | $7.91M | +146.3% | +74.6% | 3.5% | |
| Mar 2026 | $6.48M | +28.7% | +42.6% | 25.5% | |
| Mar 2026 | $3.8M | -5.1% | +29.6% | 0.9% | |
| Mar 2026 | $2.25M | +21.4% | +33.3% | 0.2% | |
| Mar 2026 | $1.6M | +62.1% | -9.6% | 3.9% | |
| Mar 2026 | $1.19M | -20.6% | +19.9% | 0.6% | |
| Mar 2026 | $880.67K | +20.3% | — | 0.9% | |
| Peer median (excluding NVCT) | $5.86M | +21.4% | +29.6% | 1.6% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.